Brad Enerson

Brad Enerson is an accomplished professional with extensive experience in nonclinical safety and toxicology within the pharmaceutical industry. As Vice President and Head of Preclinical Safety at Kymera Therapeutics from May 2020 to February 2024, Brad was accountable for the nonclinical safety strategy supporting innovative protein degraders, facilitating the accelerated development of five first-in-class degraders into clinical trials. Previously, Brad held significant roles at Decibel Therapeutics, Shire, and Pfizer, overseeing nonclinical safety strategies and study management for various drug programs, including gene therapies and biologics. Brad's early career includes a position as a Toxicologist at Wyeth. Brad earned a PhD in Biochemistry and Molecular Biology from the University of Minnesota, enhancing a solid foundation for success in the field.